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Abstract
Musculoskeletal diseases are one of the leading causes of disability worldwide. Among them, tendon
and ligament injuries represent an important aspect to consider in both athletes and active working
people. Tendon and ligament damage is an important cause of joint instability, and progresses into
early onset of osteoarthritis, pain, disability and eventually the need for joint replacement surgery.
The social and economical burden associated with these medical conditions presents a compelling
argument for greater understanding and expanding research on this issue. The particular physiology
of tendons and ligaments (avascular, hypocellular and overall structural mechanical features) makes
it difﬁcult for currently available treatments to reach a complete and long-term functional repair of
the damaged tissue, especially when complete tear occurs. Despite the effort, the treatment modalities
for tendon and ligament are suboptimal, which have led to the development of alternative therapies,
such as the delivery of growth factors, development of engineered scaffolds or the application of stem
cells, which have been approached in this review. Copyright © 2012 John Wiley & Sons, Ltd.
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1. Background
Tendon and ligament tissues have a pivotal mechanical
role in joint stability, due to their poor natural healing
capacity. Injuries in these tissues severely affect the joint
functionality, which can ultimately result in the
progression of degenerative diseases (Fleming et al.,
2005). Tendon and ligament damage is frequent and is
responsible for substantial morbidity in athletes, working
and elder population, thus representing a signiﬁcant cost
to the community in social, economic and health terms.
Currently used therapies are mainly limited to pain
control and/or tissue replacement, without fully restoring
tissue functionality.
Tissue-engineering strategies, such as growth and
differentiation factor delivery, development of engineered
scaffolds and/or the integration of stem cells, are generat-
ing potential areas for additional prospective investigation
in tendon or ligament regeneration. Nevertheless, signiﬁ-
cant challenges remain to accomplish a complete and
functional tendon and ligament repair that will lead to a
clinically effective and commercially successful application.
2. Tendon and ligament tissues:
afﬁnities and dissimilarities
Tendons and ligaments are similar dense ﬁbrous connec-
tive tissues that connect skeletal muscle to the skeletal
elements (bone) and bone to bone (Frank, 2004), respec-
tively. Both tissues are also characterized by the presence
of ﬁbroblasts/ﬁbrocytes (ligament) or tenoblasts/tenocytes
(tendon) and an abundant extracellular matrix (ECM),
mainly composed of collagen I (Gelse et al., 2003),
resulting in a dense and hypocellular structure. The
tendon matrix is maintained by the resident tenocytes,
in a continuous process of matrix remodelling.
Although the rate of ECM turnover varies at different
sites, it is strongly inﬂuenced by physical activity (Kjaer
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et al., 2005; Reeves, 2006). In pathological conditions,
other cell types, such as inﬂammatory cells, macrophages
and non-resident ﬁbroblasts, might be present in these
tissues.
Tenoblasts vary in shape and size, ranging from 20 to
70mm in length. When tenoblasts mature into tenocytes,
they became very elongated, with a width in the range
80–300mm. Tenocytes are active in generation and synthe-
sis of collagen and all other components of the ECM. The
low metabolic rate is essential to carry loads and maintain
tension of long periods, reducing the risk of ischaemia and
subsequent necrosis (Sharma and Maffulli, 2005).
Ligaments contain about two-thirds water by weight.
The remaining one-third consists mainly of collagen,
elastin, glycosaminoglycans (GAGs), cells and other
biochemical molecules (Ng, 2002). Ligaments contain
more protein, less total collagen and greater proportions
of type III collagen and GAGs than tendons (Ng, 2002).
In general, ligaments are more active than tendons.
Ligaments and tendons share physiological and constit-
uent features, with a similar hierarchical structure that
affects their mechanical behaviour. Thus, in most cases,
the regenerative approach to follow is similar, and some-
times the terms ‘tendon’ and ‘ligament’ are intermingled
in the literature. Nevertheless, these structures have dif-
ferent functional roles in the human body.
Tendons function as structural components and play a
mechanical role in linking and transmitting forces gener-
ated by muscle to bone, resulting in joint movement.
Moreover, tendons also act as springs, modulating forces
during locomotion and providing additional stability and
a signiﬁcant degree of resistance to external forces, which
also allows tendons to store and recover energy at high
efﬁciency.
The major function of ligaments is mechanical, as they
passively stabilize joints and help in guiding those joints
through their normal range of motion when a tensile load
is applied (Frank, 2004). Capsular ligaments act as me-
chanical reinforcements, while extra-capsular ligaments
join together and provide joint stability.
During development, maturation and ageing, altera-
tions in composition, structure and biomechanics occur
in tendons and ligaments (Frank, 2004; Reeves, 2006),
reducing the optimal functioning of the locomotive
system. Furthermore, mature cells are also affected by a
reduced metabolic rate and vascular supply. Although
the normal mechanical function depends on precise align-
ment of collagen ﬁbrils, proteoglycans (PGs) regulate
collagen ﬁbrillogenesis and therefore indirectly modulate
tissue function (Yoon and Halper, 2005). Furthermore,
PGs play a major role in structural and biochemical adap-
tation to changes in loading, and are thus responsible for
maintaining proper biomechanical function (Yoon and
Halper, 2005). Continued loss of PGs and other matrix
components appears to activate loss of collagen. Conse-
quently, the load absorption and redistribution properties
are less efﬁcient and render the tissue more prone to
injury. Changes in PGs expression and metabolism/turnover
have been associated with tendinopathy.
3. Tendon and ligament injuries
Tendon/ligament injuries may be caused by trauma,
tumour resection, atrophy or even shortening after
tendon laceration. These are prevalent and debilitating
lesions that affect the quality of life among populations
worldwide and can be caused by intrinsic and/or extrinsic
factors (Riley, 2004). Disease or body weight are intrinsic
factors associated with tendon injuries, although some
forms of injury may already be predisposed in patients,
such as biomechanical irregularities (anatomical and/or
functional misalignment, muscle imbalance) or genetic
susceptibility for developing full-thickness tears (Carr
et al., 2004). Extrinsic factors include environmental
conditions, prescription drugs, nutrition and lifestyle
(Maffulli et al., 2003). These factors are more common
among people whose occupations or recreational athletic
activities require repetitive motion of the shoulder, knee,
elbow or ankle joints.
The increasing levels of activity, and thus of mechanical
loading on tendon/ligament tissues, of the elder popula-
tion, is also likely to contribute to these injuries. Ageing
is involved in tendon/ligament injuries, inﬂuencing the
composition and stability of the ECM. Nevertheless,
studies performed on human patients are uncertain
regarding determining age as a risk factor in tendon/ligament
injuries (Couppe et al., 2009).
Patient gender is also a subject of debate. Although gender
is not considered a risk factor, sex hormones strongly inﬂu-
ence collagen synthesis and, as a result, tendon/ligament
composition. Moreover, anatomical differences (e.g. tendon/
ligament size) between men and women may have implica-
tions in tendon/ligament injuries (Carroll et al., 2008).
Despite all the factors mentioned above, mechanical
loading is the major factor for cellular mechanobiological
responses that may lead to tendon physiological remodel-
ling or pathological changes, such as tendinopathy.
Tendinopathy is associated with sports and physical
activity in active people over 25 years of age, and refers
to the clinical conditions in and around tendons resulting
from overload and overuse. It requires lengthy manage-
ment, and patients often respond poorly to treatment.
Frequent tendinopathies include tendinitis, which can be
described as an inﬂammatory injury, and tendinosis, often
associated with non-inﬂammatory chronic degeneration
or weakening of the tendons, which may eventually lead
to tendon rupture.
Changes in cellularity and in the remodelling activity of
tendon ECM are associated with the onset of tendinopa-
thies. The most frequently affected tendons are highly
stressed tissues, often exposed to repeated strains includ-
ing shear or compressive forces, and are relatively less
vascularized (Riley, 2004). Patellar, Achilles and hand
and foot ﬂexor tendons are among the areas most affected
by tendinopathies.
Patellar tendinopathy (PT) is a chronic painful degener-
ative condition that accounts for over 30% of sports-
related injuries (Sharma and Maffulli, 2006). Overuse of
the patellar tendon can lead to pain, tenderness,
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functional deﬁcit and disability in professional as well as
in recreational athletes. Studies on the effectiveness of
surgical treatment for PT remain inconclusive, due to the
heterogeneity of surgical procedures and the limited clinical
trials with control non-treated groups. Nevertheless,
physiotherapy may be recommended to strengthen the
muscles and tendons.
The Achilles tendon is the largest and the most power-
ful tendon in the body, enabling walking, running and
jumping. The most common Achilles tendon injuries are
Achilles tendinosis and Achilles tendon rupture, whose
damage is a debilitating occurrence. The two main types
of treatment are non-operative approaches and operative
methods (Khan et al., 2005). Non-surgical procedures
include rest, muscle strengthening, physical therapies for mis-
alignment rectiﬁcation, and non-steroidal anti-inﬂammatory
drugs. Depending on the severity of the injury, recovery
from an Achilles injury implies complete immobilization
or, in the most severe cases, surgery.
The ﬂexor tendons (FTs) in the hand and foot are highly
complex and intricate. Related injuries often lead to signiﬁ-
cant morbidity for patients and are frequently associated
with nerve and vascular injuries. Restoration of satisfactory
digital function after FT lacerations remains one of themost
challenging problems in hand surgery, as it requires the re-
establishment of the continuity of the tendon ﬁbres and of
the gliding mechanism between the tendon and its
surrounding structures (Beredjiklian, 2003).
All of the body ligaments are important to perform efﬁ-
cient physical movements. If these tissues are injured and
are not effectively repaired, normal locomotion and joint
structural integrity are compromised. The mechanisms
of ligament injury are multifactorial and can be caused
by contact or direct trauma, dynamic loading, repetitive
overuse, structural vulnerability, poor ﬂexibility, muscle
imbalance or rapid growth (Curwin, 2005). Activity-
related injuries rarely involve damage to an isolated
ligament but commonly result in a number of ligaments
being injured, with an assortment of insults occurring in
other associated tissues. The injury can happen with a
single load that exceeds its maximum strain or from
cumulative overload (repetitive sprains) with insufﬁcient
recovery time (Curwin, 2005).
Although ligaments can be composed of parallel or
random ﬁbres, ligament failure is associated with the
degree of tearing of their collagen bundles. In micro-failure,
ligaments undergo partial tearing or sprain, while great
loads will result in complete ligament damage. Although
minor ligament sprains may only cause annoyance and
minimal function loss, these injuries can progress into
severe ligament sprains, increasing functional loss. The
most commonly and severely injured ligament is the
anterior cruciate ligament (ACL), essential to knee function.
The anterior cruciate ligament (ACL) is the primary sta-
bilizer of knee motion, acting as a guide rope during the
screw-home mechanism of knee extension by preventing
anterior translation of the tibia and hyperextension of
the knee. The mechanical properties of the ACL, crucial
to its function, are complex, showing variable tension
among ﬁbre bundles and variable modulus as a function
of load level and viscoelastic effects (creep, relaxation
and strain-rate sensitivity). The ACL is the most frequently
injured knee ligament, especially in athletes, accounting
for 200 000 injuries and approximately 100 000 recon-
struction procedures reported annually in the USA alone
(Gotlin and Huie, 2000; Majewski et al., 2006). Most
patients are 20–29 years of age but gender incidence is
still a subject of debate (Majewski et al., 2006). Lateral
rotational movements cause the ACL to strain or tear.
Damage in ACL is usually accompanied by meniscus,
medial cruciate ligament and knee cartilage tears. The
most common procedure for repairing ACL injuries is
surgery. However, ACL regeneration is poor and may be
also affected by the little surrounding soft tissue available
to promote extrinsic healing. Rupture of knee ligaments
leads to instability with concomitant abnormal loading
patterns. Over time, these abnormal loads can cause joint
tissue degeneration, ultimately leading to the develop-
ment of osteoarthritis (Fleming et al., 2005).
4. Tendon/ligament healing
4.1. Natural healing mechanisms
Regeneration of ligaments and tendons is a slow process
and occurs from intrinsic or extrinsic healing or a combi-
nation of both. Although damaged tendon/ligament tends
to heal, the repair is slow and inefﬁcient after injury,
never restoring the biological and biomechanical proper-
ties completely.
The intrinsic healing mechanism results from the local
tenocytes/ﬁbrocytes, while the extrinsic healing starts
when ﬁbroblasts and inﬂammatory cells from tendon
sheath and surrounding soft tissues invade and proliferate
to lay down a new collagen matrix. Intrinsic healing is
dependent on resident cells proliferation, on an adequate
blood supply and nutrition by surrounding ﬂuids and on
the lack of adhesion formation. The involvement of exter-
nal cells in extrinsic healing also depends on the site of
injury and vascular perfusion to the lesion site. Generally,
exogenous ﬁbroblasts predominate over resident cells,
allowing the surrounding tissues to attach to the repair
site, resulting in adhesion formation.
As in any other tissue injury, inﬂammation is the
process by which tendons and ligaments heal upon dam-
age, through three sequential stages: inﬂammation, repair
and remodelling (Beredjiklian, 2003; Frank, 2004). The
goal of this inﬂammatory-reparative cascade is to regener-
ate collagen, in particular, and the ECM in general,
providing the connective tissues with strength and their
characteristic ability to handle great strain forces.
In the inﬂammatory phase, which occurs immediately
after the injury, and lasts from 24h to 5days, the inﬂamma-
tory cells migrate to the wound site, phagocytose necrotic
tissue and clot. These cells also release factors for recruiting
ﬁbroblasts to initiate collagen synthesis and deposition.
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A few days after the injury, the repair or ﬁbroblastic
phase begins. This phase, which lasts from 5days to a
few weeks, is characterized by proliferation or ﬁbroplasia.
Tendon/ligament ﬁbroblasts synthesize abundant colla-
gen and other ECM components, such as proteoglycans,
and deposit them at the wound site to increase ligament
and tendon strength.
The remodelling phase occurs between 6weeks to
9months after the original injury, when the organism
attempts to restructure the lesion to a pre-injury state.
This phase is characterized by decreased cellularity and
decreased collagen and glycosaminoglycan synthesis.
Cellular metabolism and vascularity also decline, and
the repair tissue changes to ﬁbrous tissue.
The remodelling stage can be divided into a consolida-
tion and a maturation phase. The cellular tissue becomes
more ﬁbrous and the collagen ﬁbres start to align, increas-
ing strength. At the end of the consolidation phase, at about
10–12weeks, and with the beginning of the maturation
phase, the ﬁbrous tissue is converted to a stronger scar
tissue. The tissue continues to remodel for up to 1 year.
During the healing process, several factors participate
in tissue repair. Among them, nitric oxide (NO) was
described to improve tissue healing in animal models
and to enhance clinical recovery of tendinopathies in
humans (Molloy et al., 2003).
Non-invasive pharmacological treatments using anti-
inﬂammatory medications and corticosteroids act to
minimize the deleterious side-effects of inﬂammation
and preserve tissue integrity by blocking the initial in-
ﬂammatory process of tendon/ligament healing. Never-
theless, the ﬁrst phase of repair is severely affected,
which can limit tissue complete regeneration.
Appropriate nutrition is vital for rapid healing, minimi-
zation of adhesion and restoration of gliding. In tendons,
nutrients are provided through the vascularization net-
work in addition to synovial ﬂuid diffusion, as some areas
are avascular.
Several factors have been described to affect tendon
healing, and adhesion formation, including some surgical
techniques and postoperative motion. Postoperative scar
formation, and adhesions formed between the tendon
and its surroundings are the most common complication
(Beredjiklian, 2003) and a major clinical challenge, as
scar tissue and adhesions result in the loss of normal ten-
don gliding, loss of motion, contracture formation, and
functional disability (Beredjiklian, 2003).
One of the major causes of adhesion is a tendon sheath
defect after traumatic or surgical injury. The tendon
sheath is a membrane-like structure, which acts like a bi-
ological barrier, preventing invasion of peripheral ﬁbrotic
tissue and inhibiting exogenous healing of tendon. When
this barrier is damaged, the normal functionality of the
tendon is jeopardized.
Adhesion formation is also increased after an injury,
ischaemia, immobilization and gapping at the repair site.
Such complications compromise tissue properties,
interfering with motion, gliding and consequently func-
tionality. Experimental attempts to minimize adhesion
formation embrace oral administration of steroids, antihis-
tamines or NSAIDS, topical application of hyaluronic acid,
collagen solutions or ﬁbrin, or even silicone/cellophane
wrapping, polyethylene tubes, interposed sheath ﬂaps.
Healing after injury is structure speciﬁc. As in tendons,
site-speciﬁc structural, biochemical and cellular
differences (Zhang et al., 2011b) exist in ligaments, due
to different mechanical demands and the nutritional envi-
ronment. Some ligaments, such as the medial collateral
ligament (MCL), have good healing potential, whereas
others, such as the ACL, have a poor chance of healing
after total rupture. Recently, a study conducted by Zhang
et al. (2011b) showed that adult stem cells from different
ligament tissues may behave differently in repair and
regeneration processes. Since adult stem cells play a
major role in repairing injuries, it is likely that those
dissimilarities may be related to the differential healing
capacities of the damaged tissue.
4.2. Current treatments
Tendon and ligament injuries can dramatically affect a
patient’s quality of life, and are expected to increase in
number and severity in both ageing and active population.
Tendon injuries, whether acute or chronic, are commonly
managed either conservatively or surgically. Conservative
management, such as rest, corticosteroid injection, or-
thotics, ultrasound, laser treatment or shockwave (Riley,
2004; Stergioulas et al., 2008) provide pain relief but,
when they fail, surgery is required. Surgical procedures
repair the damaged tendon in acute injuries but, in the
case of chronic tendinopathies, excision of the damaged
area might be performed. Despite the effort to improve
the quality of repaired tendons, when compared to
healthy tendons, surgically repaired tendons have inferior
functionalities. Clinical approaches frequently imply
working with degenerative tendon/ligament tissues, with
an increased risk of failure and recurrence into a second
surgery. The loss of mechanical competence is mainly
due to a distorted ECM composition and a misalignment
of collagen ﬁbrils in the scar tissue.
Besides the risks inherent to any surgery; additional
considerable risks are associated with tendon repair,
including scarring and ﬁbrous adhesion formation at the
wound site, nerve damage and infection. The failure to
achieve proper joint biomechanics must also be consid-
ered, since a partial loss of function can also lead to other
diseases, such as osteoarthritis (Fleming et al., 2005).
Ligament injuries include a complete tear, a partial tear,
a stretch injury (plastic deformation) or an alteration in
function caused by an adjacent fracture. Following a
similar path to tendon approaches, studies of ligament
healing have traditionally been focused on surgical
management and rehabilitation programmes that include
bracing and physical modalities crucial in regaining
function. In some situations, exercise may also produce
beneﬁcial effects, since ligaments are sensitive to training
and disuse.
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Similarly to tendon, the scar tissue formed in ligament
healing is mechanically inferior to normal tissue. Physio-
therapy and early joint mobilization can reduce adhesions
in these tissues, enhance vascularity and facilitate
collagen realignment and faster healing, resulting in
better gliding and higher tensile strength, preventing sub-
sequent postoperative joint stiffness.
4.2.1. Grafts
In severe damage, biological grafts may be needed to
replace damaged tendons. Nevertheless, in most cases,
grafts do not provide adequate mechanical strength
during the remodelling process.
Autografts are a currently used methodology to repair
the affected tendon, preventing instability and reducing
the rate of rerupture. Autografts may also lead to high
morbidity and functional disability at the donor site and
limited availability. Tissue laxity, mechanical mismatch
and poor tissue integration (with a possible necrosis after
implantation) are also disadvantages to be considered.
Patellar tendon and ACL tissues are commonly used
autografts for tendinopathies. Interestingly, the recon-
struction of ACL usually involves harvesting autogenous
patellar tendon or hamstring tendon grafts as ligament
substitutes (Larson, 1996).
Allografts are also alternative therapies for tendon and
ligament repair but are not ideal, due to the associated
risk of disease transmission and tissue rejection.
4.2.2. Artiﬁcial prostheses
Tendon and ligament tissues are continuously subjected
to mechanical loads, such as muscle contraction and body
movements. This natural environment is often associated
with mechanical failures that restrict the successful appli-
cation of most of the prosthetic replacements as satisfac-
tory long-term tendon or ligament substitutes.
Nevertheless, since the 1970s, several prosthetic
devices have been proposed for ligament replacement.
Some commercial products were available as ligament
substitutes, including Gore-TexW (polytetraﬂuoroethy-
lene), LarsW ligament (terephthalic polyethylene polyes-
ter – approved in Europe and Canada but not in the
USA) and Leeds-KeioW (polyester ethylene terephthalate)
(Chen et al., 2009a). Although these products showed
short-term satisfactory results, long-term studies are
ambiguous and reveal many associated complications.
Despite the fact that ligament prostheses exhibit
mechanical properties equal to or exceeding the proper-
ties of normal human tissue, prosthetics have traditionally
tended to be inadequate, due to postsurgical complica-
tions arising from wear and degeneration (Mascarenhas
and MacDonald, 2008).
The initial mechanical properties of the reconstructed
bone–ligament–bone complex depend not only on the
mechanical properties of the prosthesis but also on the
method of surgical ﬁxation to the bones, as prosthesis
stiffness and modulus can be reduced due to the effects
of surgical ﬁxation (suture, staples, screws, washers
or combinations of these methods). Additionally, a
permanent synthetic prosthesis that does not receive host
tissue ingrowth is prone to long-term mechanical failure
in the joint.
Despite all the effort, to date, no prosthesis has proven
itself as a viable alternative to autografts for primary ACL
reconstruction.
4.2.3. Graft-augmentation devices
Graft augmentation devices were developed to provide
immediate protection and share mechanical loads with
the biological graft until revascularization is complete and
the ingrowth tissue capable of withstanding local tensile
and compressive forces (Mascarenhas and MacDonald,
2008). Since these devices are meant to be temporarily
used, long-term maintenance of the mechanical properties
of the device is not necessary or even desirable. Ideally,
graft augmentation devices should be resorbable, gradually
transferring mechanical loads completely to the biological
graft. Dacron (polyethylene terephthalate) and Kennedy
LAD (braided polypropylene yarn) have been clinically
used as FDA-approved graft ligament augmentation devices
(LADs). Dacron minimizes abrasion of the graft and acts as
a scaffold for ﬁbrous tissue ingrowth (Mascarenhas and
MacDonald, 2008), while Kennedy LAD protects the graft
from excessive stresses but reveals a weak implant–graft
interface (Mascarenhas and MacDonald, 2008).
5. Strategies for repair and
regeneration: designing tendon and
ligament tissue substitutes
As described previously, currently used methodologies
mainly enable replacement or minimization of the dam-
age caused in the tissue, controlling the pain or replacing
the pathological tissue. To date, no clinical long-standing
acceptable tendon or ligament substitute is available.
Tissue engineering (TE) has offered great potential in
the treatment of tendon/ligament injuries, seeking a
biological replacement that results in a fully regenerated
living autologous tissue, mimicking the natural structure
and function and with long-term viability (Figure 1).
As dense and well-organized connective tissue, much of
tendon/ligament function is attributed to its intrinsic
structural features. These characteristics include the posi-
tioning of ECM collagen ﬁbrils according to tensile stress,
that together with high water content are responsible for
their visco-elastic and plastic properties, hence ensuring
their mechanical function and, ultimately, stabilizing the
synovial joint. These remarkable properties challenge
the design of biomaterials for modulating biological
responses into full repair and regeneration of the injury,
thus envisioning successful long-term clinical outcomes
(Table 1).
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In many soft connective tissue approaches, the mechan-
ical properties for the collagen-hierarchy reconstruction
are inﬂuenced by ﬁbre alignment. Fibre alignment is
meant primarily to mimic the resident ECM in tendon
and ligaments, although some studies report that ﬁbre
alignment can also improve the biological response of
cells seeded onto aligned scaffolds (Gigante et al., 2009;
Teh et al., 2011). In opposition, knitting (Chen et al.,
2010; Fan et al., 2009; Teh et al., 2011) or braiding
(Cooper et al., 2005; Van Eijk et al., 2007) techniques have
been described to contribute more substantially to the
mechanical robustness of the system, improving the
ability to sustain and distribute the natural loading stress.
5.1. Biological scaffolds
Biological scaffolds consist of protein-based extracellular
matrices that are mammalian-derived tissues from hu-
man, equine, porcine and bovine sources (revised by
Badylak et al., 2009; Chen et al., 2009a). Tissues such
as small intestine mucosa, pericardium or dermis are
processed to remove non-collagen components, likely
to cause rejection, while retaining the natural collagen
structure (predominantly collagen I ﬁbres) and me-
chanical properties (Chen et al., 2009a). Restore™
(porcine small intestine mucosa), OrthADAPT™ (equine
Figure 1. Schematic representation of tissue-engineered strategies for repair and regeneration of mostly injury-affected tendon and
ligament tissues
Table 1. Scaffold requirements aiming at tendon or ligament
tissue engineering
Scaffold properties Requirements
Biodegradability Degradation rate adjusted to tissue
regeneration and restore of function
Biocompatibility Do not elicit an immunological response
Interaction with the surrounding tissues
Induce host tissue integration
Processability Design different architectural structures
mimicking native tissue and addressing
tissue needs
Match tissue size and shape
Mechanical strength Ensure scaffold integrity with constant
loading
Allow active range of free movements
Prevent frictionless movements
Allow smooth and efﬁcient gliding
Biofunctionality Stimulate local environment into
regeneration
Biomechanically stable
With potential to be vascularized and
promote nutrients diffusion
Avoid adhesion formation
Assist cell inﬁltration, proliferation and
differentiation (if required) until complete
healing
Assist the delivery of therapeutic molecules
in growth factor strategies
Others Easy to handle, store and sterilize
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pericardium) or Bio-BlanketW (bovine dermis) are some
of the FDA-approved biological scaffolds for ligament
and tendon applications (Chen et al., 2009a). The
major drawback of these commercial biological scaf-
folds is that their mechanical properties are signiﬁ-
cantly lower than those of normal tendons and ligaments
(Chen et al., 2009a).
Naturally occurring scaffolds, such as small intestinal
submucosa, have been clinically used for augmentation
of the injured rotator cuff and Achilles tendon, and could
be expanded to develop engineered substitutes for ACL
(Brune et al., 2007).
Decellularized allograft tissues followed by recellulari-
zation in vitro are also another type of biological scaffold
used in tendon (Omae et al., 2009) and ligament (Tischer
et al., 2007) regenerative approaches. These scaffolds
promise advantages over allografts, as they preserve the
natural structure, biomechanical strength and stability
(Tischer et al., 2007), and because of their reduced immu-
nogenicity. Since native ECM matrices confer a unique
environment, matching tendon/ligament needs in terms
of cell attachment, proliferation, migration and gas and
nutrient/metabolite diffusion, they have themselves been
considered as scaffolds (Little et al., 2010; Zhang et al.,
2011a). Nevertheless, the efﬁciency of cell removal,
always inferior to 100%, varies accordingly to the decellu-
larization method used, viz. enzymatic, chemical, physical
or a combination of these. Whatever the method, signiﬁ-
cant drawbacks must be considered, as enzymatic
methods include animal-derived enzymes that can poten-
tially invoke an adverse immune response by the host, and
keeping in mind that the residual chemicals left after cell
removal are likely to be toxic to host cells when the
scaffold is implanted in vivo. Physical procedures may also
partially disrupt structural and functional components of
the ECM, possibly affecting the mechanical behaviour,
degradation rate and bioactivity of the biological scaffold
(Gilbert et al., 2006).
5.2. Synthetic scaffolds
Unlike biological scaffolds, synthetic commercial scaffolds
in graft-augmentation devices and artiﬁcial prostheses
can have much stronger mechanical properties than
ligament and tendon ones, but their biocompatibility is
limited (Chen et al., 2009a). In order to overcome
this problem, alternative scaffolds have been tailored,
following a TE strategy, for a more realistic application
in tendon or ligament reconstruction. Synthetic polymers
aimed at TE are typically more versatile than natural ones,
enabling tailoring and controlling chemical and physical
properties and structural features. They also represent a
more reliable source of raw materials, and low immuno-
genicity potential (Tsuji and Ishizaka, 2001).
Poly-a-hydroxyesters, such as polyglycolic acid (PGA)
(Liu et al., 2006; Stoll et al., 2011), polylactic acid (PLA)
and co-polymers (Cooper et al., 2005; Jenner et al.,
2007), have been widely used in orthopaedic TE,
including in tendon/ligament strategies. Although results
from these studies were promising, scaffolds made of
PGA, for instance, have limited application due to their
mechanical brittleness and the lack of functional groups
for signalling molecules. The manipulation of structural
parameters in the design of scaffolds and their bioactiva-
tion, through the incorporation of soluble and insoluble
signals for promoting cell activities, is likely to improve
the neoformation of tissues. Materials such as oligo[poly
(ethylene glycol) fumarate] (OPF) can be tailored to
present covalently incorporated bioactive moieties. This
feature has been explored in a hydrogel matrix as a cell
carrier system for tendon and ligament regeneration
(Doroski et al., 2010).
5.3. Natural-based scaffolds
A few scaffolds based on natural polymers have been pro-
posed for tendon regeneration. For example, silk-based
materials have shown great potential in ligament strate-
gies (Fan et al., 2009; Moreau et al., 2005; Teh et al.,
2011). Silk is a degradable and biocompatible material
with intrinsic mechanical features. To investigate the
ACL regeneration in vivo, Fan et al. (2009) developed a
scaffold by rolling a microporous ﬁbre silk mesh around
braided silk cord to increase its mechanical properties,
evidencing promising results for clinical applications.
Collagen is also a favourite material (Friess, 1998),
since collagen is the major ECM component in tendons
and ligaments. Several studies have demonstrated the
applicability of collagen gels (Haddad-Weber et al.,
2010) and multilamellar membranes (Gigante et al.,
2009) mediating tendon repair, including in animal
models (Awad et al., 1999). Nevertheless, several disad-
vantages of collagen-based scaffolds should be considered
when aiming at a tendon/ligament substitute (Friess,
1998), including cost, variations from batch to batch and
the possibility of immunogenic and disease transmission
risks (Friess, 1998).
Fibrin is another natural biomaterial that has been
proposed as a matrix for tendon and ligament strategies
(Bayer et al., 2010; Hankemeier et al., 2009). Fibrin is a
ﬁbrous protein naturally involved in the clotting of blood,
which polymerizes to form a haemostatic plug or clot over
a wound site. Additionally, ﬁbrin is a biodegradable and
bioresorbable structure that can be used to encapsulate
cells in a stable way (Hankemeier et al., 2009), thus
acting as a supportive gel for assisting collagen ﬁbrillono-
genesis (Bayer et al., 2010) or through controlled delivery of
growth factors stimulating the biological response towards
tendon/ligament repair (Thomopoulos et al., 2007).
The combination of different biomaterials is also a
strategic design for achieving hybrid scaffolds
(Chen et al., 2010). Silk–collagen hybrid scaffolds devel-
oped in a knitted sponge matrix have been described, as
well as the application of alginate and chitosan hybrid
ﬁbres to support tendon ﬁbroblast adhesion (Shimode
et al., 2009).
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Other polymers, including polysaccharides and
proteins that share similar features with the natural
ECM (revised by Mano et al., 2007), have shown interest-
ing properties and outcomes in several tissues (Silva et al.,
2010) and may also have a potential application in
scaffold design for the tendon/ligament ﬁeld.
5.4. Cell sources for tendon/ligament
The newborn tendon has a very high cell:matrix ratio that
decreases during development, maturation and ageing,
supporting the importance of the cellular contribution in
tissue maintenance and functionality. The most wide-
spread TE approach is to reconstruct a ligament/tendon
by providing a scaffold seeded with cell-inducing
neotissue formation that adequately meets the required
biological and mechanical properties. The development
of TE products with the application of appropriate types
of cells could potentially improve the functionality and
structure of tissue-engineered constructs. Cell-based
therapies offer the potential to induce a regenerative
response, rather than ﬁbrous scarring, by stimulating
local cells to proliferate and inspire the production of a
structural matrix to ensure remodelling as the implant
scaffold degrades.
Autologous cells are likely to provide an optimal
approach to address a structural and functional replace-
ment, avoiding immune reactions or morbidity caused by
grafts. Tenocytes represent an obvious choice (Liu et al.,
2006) that has been addressed in engineered strategies
(Cooper et al., 2006; Gigante et al., 2009; Stoll et al.,
2011). Tenocyte isolation and culture from different
anatomical sites, such as at the rotator cuff (Pauly et al.,
2010), patellar and Achilles tendons (Bernard-Beaubois
et al., 1997; Bayer et al., 2010; Zhang and Wang, 2010),
is feasible, but tenoblasts/tenocytes are scarce cells and
thus increase tissue morbidity at the harvesting site, creat-
ing an undesirable side-defect.
Recent studies suggested the application of cells
harvested from either intact (Brune et al., 2007; Cooper
et al., 2005) or ruptured (Brune et al., 2007) ACL for TE
approaches. Other studies mention harvesting patellar ten-
don samples during reconstruction of the ACL (Hankemeier
et al., 2009). Despite the fact that ﬁbroblasts obtained from
damaged tissue could provide an interesting cell source, the
availability of native cells might be limited and their func-
tionality might be compromised, depending on the condi-
tions and dimensions of the damaged tissue.
Dermis ﬁbroblasts (DFs) are an easily accessible source of
cells that has also been explored for tendon and ligament
repair (Gigante et al., 2009; Van Eijk et al., 2007; Tischer
et al., 2007), including for autologous approaches (Liu
et al., 2006). DFs are commonly harvested from native
tissue through a skin biopsy, which is a simple, timeless
and cost-effective procedure and easily expanded during
in vitro culture. More importantly, DFs share common char-
acteristics with tenocytes, as both cell types are terminally
differentiated cells and originated from mesoderm.
Also from an autologous source are cells obtained from
the tendon sheath (Xu et al., 2010), a membrane-like
structure that involves tendons, separating tendon from
the surrounding tissue and assuring tendon gliding.
Nevertheless, disruption of the tendon sheath seriously
interferes with normal tendon functionality, and
consequently the isolation of these cells may severely
compromise the healing approach, causing more damage
than therapeutic outcomes.
The concept of using stem cells to accelerate repair and
tissue regeneration has been established for various
tissues, including cartilage or bone (revised by Rodrigues
et al., 2011), showing its potential for future clinical out-
comes. Considering the high self-renewal capacity and
the ability to differentiate into several lineages, stem cells
could improve the cellular density and proliferation rates
at the tendon/ligament injuries. On account of the loca-
tion and environmental milieu, resident stem cells from
ligament and tendon tissues are an interesting source for
tissue-regeneration approaches (Bi et al., 2007; Cheng
et al., 2010; Lui and Chan, 2011; Murchison et al., 2007;
Steinert et al., 2011; Zhang et al., 2011a). However,
despite their potential, harvesting these cells might result
in side-effects similar to those caused by tenoblast and
ligament ﬁbroblast procedures.
The synovial membrane that surrounds the posterior
cruciate ligament would be a likely source of cells, espe-
cially for ACL. Synovial cells not only have a multi-lineage
potential but also, in an untreated damage, these cells are
likely to reach and colonize the injury site (Messenger
et al., 2010).
Although it is very likely that all mesenchymal stem
cells may become tendon-capable cells, stem cell-based
strategies aiming at tendon and ligament studies have
mainly approached bone marrow stem cells (BMSCs)
(Awad et al., 1999; Cheng et al., 2010; Doroski et al.,
2010; Fan et al., 2009; Hankemeier et al., 2009; Jenner
et al., 2007; Moreau et al., 2005; Omae et al., 2009;
Shimode et al., 2009; Teh et al., 2011). Interestingly, sev-
eral comparative studies have been developed in the last
few years, providing novel data concerning the search
for the ideal cell source for tendon/ligament regeneration
(Cheng et al., 2010; Cooper et al., 2006; Hankemeier et al.,
2009; Van Eijk et al., 2007). For example, a comparative
study between stem cells isolated from human ACL (LSCs)
and bone marrow (BMSCs) from the same donors indi-
cated that LSCs proliferated faster and maintained an
undifferentiated state under basic ﬁbroblast growth factor
(bFGF) stimulation (Cheng et al., 2010). Moreover, when
treated with transforming growth factor- b1 (TGFb1),
LSCs upregulated major tendinous gene expression and
produced a robust amount of ligament ECM protein
(Cheng et al., 2010). When BMSCs were compared to
mature ﬁbroblasts encapsulated in a ﬁbrin matrix, the
results indicated that the molecular and biochemical para-
meters of tendon healing were enhanced in the presence
of BMSCs (Hankemeier et al., 2009). The presence of
BMSCs in window patellar tendon defect also mediates
tendon repair outcomes, with a signiﬁcant increment in
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maximum stress, modulus and strain energy density
(Awad et al., 1999). Van Eijk et al. (2007) compared
BMSCs, DFs and ACL cells with regard to in vitro prolifer-
ation and matrix production when seeded onto a PLGA
multiﬁlament scaffold. Preliminary results based on a
single donor indicated that BMSCs were the most promis-
ing for application in ligament TE, followed by skin
ﬁbroblasts, whereas ACL ﬁbroblasts seemed of limited
application (Van Eijk et al., 2007). Concerning the
parameters analysed in these comparative revisions, the
stemness factor is likely to increase the cell potential in
tendon/ligament TE.
The utilization of adipose tissue stem cells (ASCs) for
tendon regeneration has recently been considered (Little
et al., 2010; Park et al., 2010). ASCs present a high poten-
tial of application for TE and regenerative medicine
approaches, as ASCs are easily differentiated into several
lineages and the harvesting procedure causes minimal do-
nor site morbidity and enables a large amount of tissue
and cells to be obtained (Rada et al., 2009).
The most signiﬁcant drawback using progenitor cells
in vivo is the potential formation of ectopic bone and car-
tilage at the tendon/ligament site, due to their multipo-
tential capacity and common origin (Cohen et al., 2010).
The wide-spectrum potential for differentiation makes
fetal (Watts et al., 2011) or embryonic-derived stem cells
(ESCs) (Chen et al., 2009b, 2010) another attractive
cell source for healing and regenerative approaches.
As with other SCs, ESCs application for tendon or liga-
ment strategies has been barely explored (Chen et al.,
2009b; Cohen et al., 2010), although evidence of
success using connective tissue progenitor cells derived
from ESCs has recently been reported in mouse Achilles
tendon (Cohen et al., 2010).
Since no speciﬁc soluble factors to encourage tenogen-
esis have been identiﬁed, the study of tenogenesis in
adults and tenogenic differentiation has been deterred
by the lack of speciﬁc tendon markers.
Despite the different functions of connective tissue of
cartilage, tendons, ligaments and fascia, these cells
share a predominant origin from the embryonic meso-
dermal layer (Montero et al., 2011). Thus, the different
phenotypic appearance is likely to be based on speciﬁc
patterns of gene expression modulated by environmental
factors. Several molecules associated to tendon/ligament
formation and development are listed in Table 2, viz.
TGFb (Pryce et al., 2009), scleraxis (Murchison et al.,
2007; Schweitzer et al., 2001; Shukunami et al.,
2006) and several members of the small leucine-rich
proteoglycans (SLRPs) (revised by (Banos et al.,
2008), e.g. decorin and tenomodulin (Docheva et al.,
2005; Shukunami et al., 2006). The natural presence
of collagens I and III in tendon/ligament ECM has also
been screened for normal tendon/ligament develop-
ment approaches (Liu et al., 2011; Shukunami et al.,
2006), and for the characterization of mature tendon/
ligament cells.
However, there are still clear limitations in deﬁning op-
timal conditions for tenogenic differentiation and markers
to assess tenocyte/ﬁbroblast phenotype. Genetically mod-
iﬁed cells to produce and release higher amounts of the
desired therapeutic factor are another option in cell-based
strategies towards tendon/ligament regeneration.
Preliminary studies have been conducted with TGFb1
cDNA-transduced BMSCs grafts for acceleration and
improvement of Achilles tendon healing in a rabbit model
(Hou et al., 2009). In the ligamentogenic ﬁeld, Haddad-
Weber et al. (2010) described the inﬂuence of transduced
bone morphogenic protein-12 (BMP-12) and BMP-13
genes (also known as growth and differentiation factors
GDF-5 and GDF-6, respectively) in the ligament differenti-
ation process of BMSCs and ACL ﬁbroblasts. After 21 days
of cell culture within collagen I hydrogels, both cell types
revealed a ﬁbroblastic-like morphology. Nevertheless,
BMSCs and ACLs differently expressed ligament-related
markers, such as collagen III, decorin, scleraxis, tenascin
and tenomodulin.
Table 2. Molecules associated with tendon and ligament for-
mation and development
Transcription factors Function in tendon/ligament tissues
TGF-b Inducer of tendon markers in mesenchymal
cells (Pryce et al., 2009)
Signiﬁcant role in the genesis of tendons
and ligaments (Pryce et al., 2009)
Scleraxis Considered a speciﬁc marker for tendon
progenitor cells
Associated to tendon differentiation and
ECM organization
Participates in the formation of force-
transmitting tendons (Schweitzer et al.,
2001)
Highly expressed in tendon stem/progenitor
cells (TSPCs) (Murchison et al., 2007)
Decorin (SLRPs) The most abundant PGs in tendon; binds to
TGF and EGF (Yoon and Halper, 2005)
Stabilizes and aligns collagen ﬁbrils during
ﬁbrinogenesis and contributes to tendon
strength and elasticity (revised by Banos
et al., 2008)
Tenomodulin Regulator of tenocyte proliferation
Involved in collagen ﬁbril maturation
(Docheva et al., 2005)
Highly expressed in tendon stem/progenitor
cells (Murchison et al., 2007)
Involved in the organization of TSPCs niche,
which in turn controls the fate of TSPCs (Bi
et al., 2007)
Fibromodulin Binds to type I collagen
Facilitates formation of mature large
collagen ﬁbrils
Involved in the modulation of tendon
strength (Yoon and Halper, 2005)
Biglycan (SLRPs) Role in the regulation of collagen
ﬁbrillogenesis during tendon development
(revised by Banos et al., 2008)
Involved in the organization of TSPCs niche,
which in turn controls the fate of TSPCs (Bi
et al., 2007)
Collagen I The major collagen of tendons
Provides tensile stiffness (Gelse et al., 2003)
Collagen III Structurally similar to collagen I; important
role in collagen I ﬁbrillogenesis (revised by
Banos et al., 2008)
Widely distributed in collagen I-containing
tissues (Gelse et al., 2003)
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5.5. The role of growth factors in tendon/
ligament regeneration
The tissue repair process is a complex cascade of biologi-
cal events, orchestrated by numerous cytokines and
growth factors. Repairs to tendon/ligament injuries are
no exception. The delivery of humoral factors at
the required dosages in a temporal and spatial pattern
over the repair phase is critical to achieve a successful
treatment. Scaffolds, microspheres and micro- or nano-
capsules have been shown to be promising vehicles for
growth factor delivery. Such technologies could provide
crucial ﬁndings in regenerative medicine by controlling
the spatiotemporal release of these molecules, ensuring
long-term stability and storage of these factors in tailored
systems. Despite the potential of these technologies,
tendon/ligament tissues remain an unexplored ﬁeld of
interest.
Several growth factors are described to participate in
tendon/ligament formation, ECM synthesis or healing,
such as TGFb (Pryce et al., 2009), insulin growth factor-1
(IGF-1; Olesen et al., 2006), platelet-derived growth fac-
tor (PDGF; Thomopoulos et al., 2007), bFGF (Cheng
et al., 2010) or vascular endothelial growth factor (VEGF;
Pufe et al., 2001). Other molecules, such as nitric oxide,
have also been described to inﬂuence the volume of
synthesized tissue during tendon healing (Molloy et al.,
2003; Murrell et al., 1997) and to modulate gene expres-
sion and cellular adhesion of tenocytes (Molloy et al.,
2003). When released at the site of injury, these growth
factors modify cell proliferation, migration, differentia-
tion and matrix synthesis, which could play a key role in
stimulating local ECM production and local tenocytes
(Liu et al., 2011). Table 3 summarizes growth factors that
have been associated with the development of engi-
neered tendon and ligament tissues. Sequential growth
factor application in silk–BMSC engineered constructs
has been proposed by Moreau et al. (2005). The idea
was to assist BMSCs proliferation, providing FGF or epi-
dermal growth factor (EGF) during the ﬁrst days, and
then to stimulate cell differentiation in the silk matrices
for ECM production with TGFb1 for an additional 9days
(Moreau et al., 2005). Although a signiﬁcant increase in col-
lagen type I transcript expression was observed in most con-
ditions from day 5 of culture to day 14, mechanical integrity
decreased in time, revealing the complexity of mechanisms
and cell behaviour responses towards GF stimuli.
5.5.1. Platelet-rich solutions
Growing evidence on platelet-rich solutions suggests their
application in tendon/ligament strategies (Anitua et al.,
2005; Bosch et al., 2010; de Vos et al., 2010). Platelet-rich
plasma (PRP) results from whole blood processing in
order to obtain a high concentration of platelets. Platelets
are a source of numerous growth factors which are
released upon activation, including those involved in the
repair and regeneration of several tissues. As an autolo-
gous biomaterial, PRP is immune- and transmissible
disease-free, while combining the synergistic effect of mul-
tiple endogenous growth factors. Local injection of PRP has
been associated with enhanced migration of circulation-
derived cells into the wound site at an early phase of the
tendon healing process (Kajikawa et al., 2008). Anitua
et al. (2005) also suggested that autologous protein and
growth factors released from plasma clots and platelets
act on human tendon cells, promoting proliferation and
inducing the synthesis of angiogenic growth factors. Fur-
thermore, PRP treatment could provide a less invasive
alternative to surgery by promoting safe and natural
healing. Nevertheless, pilot clinical trials on PRP thera-
pies applied to tendinopathies in the Achilles tendon
revealed inconclusive results (de Vos et al., 2010). Thus,
understanding how PRP affects the healing processes of
various musculoskeletal tissues could provide important
cues in the factors and factor concentrations towards
effective tendon/ligament regeneration.
5.6. Bioreactors
Tendons respond to mechanical forces by changing the
metabolism as well as their structural and mechanical
properties, which is commonly designated by tissue
mechanical adaptation. Without the appropriate biome-
chanical cues, new tissue formation lacks the necessary
collagenous organization and alignment for sufﬁcient
load-bearing capacity (Benhardt and Cosgriff-Hernandez,
2009). Mechanical loading of human tendon does result
in a marked interstitial increase in growth factors that
are known to stimulate synthesis of collagen and other
Table 3. Growth factors associated to engineered tendon and
ligament tissues
Function in engineered tendon/ligament
TGFb TGFb1 stimulates upregulation of gene
expression and production of ECM in LSCs
(Cheng et al., 2010).
Associated with tendon formation, TGFb
signalling is a potent inducer of tendon markers
in mesenchymal cells (Pryce et al., 2009).
Increases hBMSCs proliferation in braided PLGA
scaffolds (Jenner et al., 2007).
bFGF Maintains undifferentiated state of LSCs and
fastens cell proliferation (Cheng et al., 2010).
VEGF Involved in tendon graft remodelling (Petersen
et al., 2003).
Produced in vitro after plasma clots and platelets
stimuli by tendon cells (Anitua et al., 2005).
PDGF Controlled delivery of PDGF-BB enhanced the
biologic response of canine repaired ﬂexor
tendons (Thomopoulos et al., 2007).
BMPs or GDFs GDF-5 increases hBMSCs proliferation in braided
PLGA scaffolds (Jenner et al., 2007).
In ASCs, GDF-5 also led to increased proliferation
and enhanced ECM and tendonogenic markers
(Park et al., 2010).
GDF-5 deﬁciency in mice results in delayed
Achilles tendon repair (Chhabra et al., 2003).
HGF Produced in vitro after plasma clots and platelets
stimuli by tendon cells (Anitua et al., 2005).
LSCs, ligament stem cells; HGF, hepatocyte growth factor.
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ECM proteins (Kjaer et al., 2005). Therefore, bioreactors
are an important tool in TE strategies, providing dynamic
environments and mechanical stimulation to guide tissue
remodelling and improve the performance of tendon/lig-
ament tissue substitutes (Chen et al., 2010; Doroski
et al., 2010; Messenger et al., 2010).
In fact, Chen et al. (2010) showed that dynamic
mechanical stress directed ESCs, seeded onto a collagen-
silk scaffold, into a tenocyte-like morphology, demon-
strated by the positive expression of tendon-related
markers such as collagen I and scleraxis, as well as
mechano-sensory organelles and molecules, namely cilia,
myosin and integrins (Chen et al., 2010). Several studies
have reported that mechanical conditioning positively
affected cell proliferation and differentiation and
increases tendon/ligament ECM synthesis (Doroski et al.,
2010; Messenger et al., 2010). Cyclic strain signiﬁcantly
upregulated the collagen I, collagen III and tenascin-C
genes of BMSCs after 21 days in culture, whereas genes
for other pathways (osteogenic, chondrogenic and adipo-
genic) did not increase (Doroski et al., 2010). Addition-
ally, cyclic tensile strain may also interfere in the
alignment of collagen ﬁbrils in the ECM. Preliminary
studies indicate that, at a certain amplitude, ECM ﬁbres
aligned along the direction of the strain application,
whereas in the control group the ﬁbres were randomly
oriented (Messenger et al., 2010).
5.7. Animal models
Despite the effort to solve tendon/ligament ruptures, few
successful approaches have been achieved to completely
regenerate these tissues. Animal models can greatly
contribute to understanding the physiology and biome-
chanics of tendon/ligament repair mechanisms and
provide the ultimate outcomes regarding the functionality
of tissue engineered constructs.
For a better understanding about the mechanisms
associated with ligament and tendon healing, as well as
to assess the functionality of different regenerative
therapies, several animal models have been studied,
considering the type and degree of injury (Carpenter
and Hankenson, 2004; Goh et al., 2003). Hens have been
proposed as experimental models for ﬂexon tendon stud-
ies and tendon sheath (Xu et al., 2010). Hen tendons are
large enough for laceration and repair studies and are
described to be an excellent model for studying the forma-
tion and prevention of adhesions. Conversely, the tendon-
sheath complex is an integrated structure, important for
tendon function in hand and foot, where very efﬁcient lu-
brication is required, due to intense mechanical stress
(Sharma and Maffulli, 2005). Recently, an in vivo
reconstruction of a tendon sheath was successful per-
formed using tendon sheath-derived cells and polyglycolic
acid (PGA) ﬁbres in a Leghorn hen model (Xu et al.,
2010).
The ligament size of mice and rats and the constant
remodelling of the musculoskeletal system during the
lifetime of the animals can be major drawbacks to con-
sider in the interpretation of functional and biological
outcomes. Nevertheless, rats and mice represent encoura-
geing species for genetic engineering manipulations,
useful for elucidating basic biological processes, studying
gene relationships and disease phenotypes, towards mod-
elling human clinical conditions. These animals yield
exciting new insights into the study of tendon/ligament
injuries and associated diseases in biomedical research
(Docheva et al., 2005; Kajikawa et al., 2008; Murrell
et al., 1997; Zhang et al., 2011a), as well as mechanisms
of tendon/ligament development and healing (Chhabra
et al., 2003; Cohen et al., 2010; Hankemeier et al., 2009;
Pryce et al., 2009). Some studies have investigated a rat
patellar tendon model treated with ESCs (Chen et al.,
2009b), showing in situ structural and mechanical
improvement; furthermore, the cells secreted matrix and
differentiated factors resulting in the stimulation of the
endogenous regeneration process in tendon (Chen et al.,
2009b).
The biochemical and functional properties of rabbit
tendons have been well documented in biomedical
research (Awad et al., 1999; Katsura et al., 2006; Stoll
et al., 2011). However, the rabbit spends most of its life-
time in ventral recumbency with deeper knee ﬂexion than
in larger animals, such as goat, sheep or pig. Besides,
rabbit posterior knees have stronger muscles and
tendon/ligament structures, which may make it more
difﬁcult to mimic human tissue before and during regen-
eration. Studies on tendon properties (Dressler et al.,
2002; Katsura et al., 2006) and patellar (Awad et al.,
1999) and Achilles tendon (Stoll et al., 2011) regenera-
tion strategies have been evaluated in the lapine model.
Dogs have also been recognized in tendon/ligament
experimental models (Thomopoulos et al., 2007) but are
not so frequently used, due to the proximity of dogs to
humans as companion animals. Nevertheless, several
studies focus on canine ﬂexor tendons because of the sim-
ilarity to those of humans (Thomopoulos et al., 2007).
The larger joint size in goat and sheep suggests that
they are ideally suited for cruciate ligament grafting and
reconstructions (Petersen et al., 2003). Other studies on
the healing properties of adult and fetal tendons have also
been considered in sheep models aiming at novel thera-
peutic strategies in the clinical set (Beredjiklian et al.,
2003).
The degree of ﬂexion in the stiﬂe joints of goats and
sheep suggests a closer analogy to human knee joints,
despite dissimilarities in magnitude and direction of force
in both the anteromedial and posterolateral bundles of
ACL (Fan et al., 2009).
Pig anatomy also presents some limitations when
compared to humans. For instance, the pig knee differs
from that of the human in the magnitude and direction
of force in the posterior lateral bundle of the ACL (Fan
et al., 2009). Nevertheless, a study performed with
BMSCs and a silk scaffold for ACL regeneration revealed
that the regenerated ligament showed similarities to the
native ACL, both in ECM composition and mechanical
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properties (Fan et al., 2009). Hybrid pigs are also a model
for autologous approaches. Liu et al. (2006) tissue-
engineered autologous dermal ﬁbroblasts and tenocytes
with PGA unwoven ﬁbre scaffolds as a strategy to repair a
defect of the ﬂexor digital superﬁcial tendon. The results
indicated that engineered tendonswith both cell types exhib-
ited similar macroscopic, histological and biomechanical
features, with the neotissue histology showing a regular
structure similar to that of normal tendon.
Horses are not a conventional and easily available
model for human clinical outcomes, due to the demand-
ing and expensive housing, handling and care of these
animals. Nevertheless, horses represent a substantial
value for the related sports and recreational activities,
and hold great promise as a model for a wide range of
medical conditions found in both horses and humans,
predicting potential human outcomes. In the last few
years, studies have been published describing various
tendon-engineered strategies, including the development
of equine induced pluripotent stem (iPS) cells (Nagy
et al., 2011) and research on cell therapies. These
approaches are not only promising for equine therapies
but allow the validation of stem cell-based therapies in
a large animal model, before moving into the human
clinical scenario (Nagy et al., 2011). Another frequent
study line is the use of horses for evaluating repair
mechanisms of the superﬁcial digital ﬂexor tendon
(Bosch et al., 2010; Watts et al., 2011). Watts et al.
(2011) investigated the inﬂuence of intralesional injec-
tion of fetal-derived embryonic-like stem cells in the
healing of tendonitis, verifying that tendon architecture
and the lesion size were signiﬁcantly improved in the
fdESC-treated tendons.
6. Conclusions and remarks on the
future
At the beginning of the twenty-ﬁrst century, the study of
tendon/ligament tissue regeneration is barely explored.
Nevertheless, tendon/ligament injuries are quite fre-
quent, affecting young and older patients, and result in
considerable disability, which can aggravate into other pa-
thologies, such as osteoarthritis. Since the working-age
population is also affected, damage is also related to loss
of working capability and health care costs.
The development of new strategies to stimulate and
interact with the in vivo environment, enhancing the heal-
ing and functionality of tendon/ligament tissues, may
yield more successful outcomes for clinical treatments
than graft surgery replacements. A wide range of poten-
tial biomaterials are to be investigated, considering
tendon/ligament features in general and the speciﬁc
properties and needs of tendon/ligament in each anatom-
ical region of interest.
The replacement of injured tissues requires cells to
maintain and proliferate with the desired phenotype in
order to achieve complete functionality. Since tenocyte
harvesting is associated with severe disadvantages to the
donor site, and might not be applicable in clinical cases;
novel possibilities with stem cells are to be explored to
better mimic the biophysical and biochemical milieu,
enhancing ligament and tendon healing. The develop-
ment of a speciﬁc expansion and differentiation medium
could also accelerate the spreading of stem cell-based
strategies for tendon/ligament.
Growing evidence on embryonic development can pro-
vide important clues towards promising developments on
tissue-engineering products aiming at successful clinical
methodologies in tendon/ligament tissues (Figure 1).
The importance of growth factor release in the healing
process should also be considered, especially looking at
growth factors that participate in tendon/ligament
healing.
Considering that mechanical stimulus is an important
niche for tendon/ligament development after birth and
essential for a healthy and functional tissue, bioreactors
may have a pivotal role in repair and regeneration of these
tissues.
Future steps should include the optimization of the ac-
quired knowledge and combination among the systems
proposed, considering the advantages and disadvantages
of each technique or procedure. Growing evidence on
biological features in the body, including ECM biology,
immunology and cell–cell and cell–scaffold interactions,
will provide a better understanding of how the body
responds to speciﬁc materials and will assist the scaffold-
ing design of novel and functional structures that will
mimic and fulﬁl the structural and biochemical needs of
a desirable supportive device. A successful integration of
scientiﬁc information will provide understanding and evo-
lution of a tissue-engineered product aiming at practical
tendon/ligament regeneration.
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